SHStephen L. Hoffman

Stephen L. Hoffman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Stephen L. Hoffman has a total of 44 co-authors. Here are the top co-authors by number of shared publications:

  • Daniel J. Carucci

    Malaria Program, Naval Medical Research Center, 503 Robert Grant Avenue, Silver Spring, MD 20910; †Henry M. Jackson Foundation, Rockville, MD 20852; §United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702; ‖Vical Incorporated, San Diego, CA 92121; **Bioject Inc., Portland, OR 97224; and ‡‡School of Hygiene and Public Health, Johns Hopkins University, Baltimore, MD 21205-2129

    2 shared publications
  • Denise L. Doolan

    Centre for Molecular Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, QLD, Australia

    2 shared publications
  • John Sacci

    Malaria Program, Naval Medical Research Center , Silver Spring 6 Department of Microbiology, University of Maryland School of Medicine , Baltimore

    2 shared publications
  • Martha Sedegah

    Malaria Program, Naval Medical Research Center , Silver Spring 6 Department of Microbiology, University of Maryland School of Medicine , Baltimore

    2 shared publications
  • Thomas Richie

    Sanaria Inc., Rockville, USA

    2 shared publications
  • Trevor R. Jones

    Malaria Program, Naval Medical Research Center, 503 Robert Grant Avenue, Silver Spring, MD 20910; †Henry M. Jackson Foundation, Rockville, MD 20852; §United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702; ‖Vical Incorporated, San Diego, CA 92121; **Bioject Inc., Portland, OR 97224; and ‡‡School of Hygiene and Public Health, Johns Hopkins University, Baltimore, MD 21205-2129

    2 shared publications

Latest Publications

  • Top Cited Papers
    Open Access

    Protection of Humans against Malaria by Immunization with Radiation‐AttenuatedPlasmodium falciparumSporozoites

    by Stephen L. Hoffman, Lucy M. L. Goh, Thomas C. Luke, Imogene Schneider, Thong P. Le, Denise L. Doolan, John Sacci, Patricia de la Vega, Megan Dowler, Chris Paul, et al.

    During 1989–1999, 11 volunteers were immunized by the bites of 1001–2927 irradiated mosquitoes harboring infectious sporozoites of Plasmodium falcipa


  • Plasmodium, human and Anopheles genomics and malaria

    by Stephen L. Hoffman, G. Mani Subramanian, Frank H. Collins, J. Craig Venter

    The Plasmodium spp. parasites that cause malaria are transmitted to humans by Anopheles spp. mosquitoes. Scientists have now amassed a great body of knowledge about the parasite, its mosquito vector and human host. Yet this year there will be 300–500 million new malaria infections and 1–3 million deaths caused by the disease. We believe that integrated analyses of genome sequence, DNA polymorphisms, and messenger RNA and protein expression profiles will lead to greater understanding of the molecular basis of vector–human and host–parasite interactions and provide strategies to build upon these insights to develop interventions to mitigate human morbidity and mortality from malaria.


  • Open Access

    Codon Optimization of Gene Fragments Encoding Plasmodium falciparum Merzoite Proteins Enhances DNA Vaccine Protein Expression and Immunogenicity in Mice

    by David L. Narum, Sanjai Kumar, William O. Rogers, Steven R. Fuhrmann, Hong Liang, Miranda Oakley, Alem Taye, B. Kim Lee Sim, Stephen L. Hoffman

    In contrast to conventional vaccines, DNA and other subunit vaccines exclusively utilize host cell molecules for transcription and translation of proteins. The adenine plus thymine content of Plasmodium falciparum gene sequences (∼80%) is much greater than that of Homo sapiens (∼59%); consequently, codon usage is markedly different. We hypothesized that modifying codon usage of P. falciparum genes encoded by DNA vaccines from that used by the parasite to those resembling mammalian codon usage would lead to increased P. falciparum protein expression in vitro in mouse cells and increased antibody responses in DNA-vaccinated mice. We synthesized gene fragments encoding the receptor-binding domain of the 175-kDa P. falciparum erythrocyte-binding protein (EBA-175 region II) and the 42-kDa C-terminal processed fragment of the P. falciparum merozoite surface protein 1 (MSP-1 42 ) using the most frequently occurring codon in mammals to code for each amino acid, and inserted the synthetic genes in DNA vaccine plasmids. In in vitro transient-expression assays, plasmids containing codon-optimized synthetic gene fragments (pS plasmids) showed greater than fourfold increased protein expression in mouse cells compared to those containing native gene fragments (pN plasmids). In mice immunized with 0.5, 5.0, or 50 μg of the DNA plasmids, the dose of DNA required to induce equivalent antibody titers was 10- to 100-fold lower for pS than for pN plasmids. These data demonstrate that optimizing codon usage in DNA vaccines can improve protein expression and consequently the immunogenicity of gene fragments in DNA vaccines for organisms whose codon usage differs substantially from that of mammals.


  • Induction of CD4+T cell-dependent CD8+type 1 responses in humans by a malaria DNA vaccine

    by Ruobing Wang, Judith Epstein, Fe Maria Baraceros, Edward J. Gorak, Yupin Charoenvit, Daniel J. Carucci, Richard C. Hedstrom, Nancy Rahardjo, Tanya Gay, Peter Hobart, et al.

    We assessed immunogenicity of a malaria DNA vaccine administered by needle i.m. or needleless jet injection [i.m. or i.m./intradermally (i.d.)] in 14 volunteers. Antigen-specific IFN-γ responses were detected by enzyme-linked immunospot (ELISPOT) assays in all subjects to multiple 9- to 23-aa peptides containing class I and/or class II restricted epitopes, and were dependent on both CD8+and CD4+T cells. Overall, frequency of response was significantly greater after i.m. jet injection. CD8+-dependent cytotoxic T lymphocytes (CTL) were detected in 8/14 volunteers. Demonstration in humans of elicitation of the class I restricted IFN-γ responses we believe necessary for protection against the liver stage of malaria parasites brings us closer to an effective malaria vaccine.


  • Immunogenicity and Protective Efficacy of aPlasmodium yoeliiHsp60 DNA Vaccine in BALB/c Mice

    by Gloria I. Sanchez, Martha Sedegah, William O. Rogers, Trevor R. Jones, John Sacci, Adam Witney, Daniel J. Carucci, Nirbhay Kumar, Stephen L. Hoffman

    The gene encoding the 60-kDa heat shock protein ofPlasmodium yoelii(PyHsp60) was cloned into the VR1012 and VR1020 mammalian expression vectors. Groups of 10 BALB/c mice were immunized intramuscularly at 0, 3, and 9 weeks with 100 μg of PyHsp60 DNA vaccine alone or in combination with 30 μg of pmurGMCSF. Sera from immunized mice but not from vector control groups recognizedP. yoeliisporozoites, liver stages, and infected erythrocytes in an indirect fluorescent antibody test. Two weeks after the last immunization, mice were challenged with 50P. yoeliisporozoites. In one experiment the vaccine pPyHsp60-VR1012 used in combination with pmurGMCSF gave 40% protection (Fisher's exact test;P= 0.03, vaccinated versus control groups). In a second experiment this vaccine did not protect any of the immunized mice but induced a delay in the onset of parasitemia. In neither experiment was there any evidence of a protective effect against the asexual erythrocytic stage of the life cycle. In a third experiment mice were primed with PyHsp60 DNA, were boosted 2 weeks later with 2 × 103irradiatedP. yoeliisporozoites, and were challenged several weeks later. The presence of PyHsp60 in the immunization regimen did not lead to reduced blood-stage infection or development of parasites in hepatocytes. PyHsp60 DNA vaccines were immunogenic in BALB/c mice but did not consistently, completely protect against sporozoite challenge. The observation that in some of the PyHsp60 DNA vaccine-immunized mice there was protection against infection or a delay in the onset of parasitemia after sporozoite challenge deserves further evaluation.